Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 10Cerdelga
Main Therapeutic Indication : Rare Disorders
Currency : USD
2019 Revenue in Millions : 225
2018 Revenue in Millions : 173
Growth (%) : 30
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 283
2019 Revenue in Millions : 249
Growth (%) : 14
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 280
2020 Revenue in Millions : 255
Growth (%) : 9
Main Therapeutic Indication : Rare Diseases
Currency : USD
2022 Revenue in Millions : 316
2021 Revenue in Millions : 280
Growth (%) : 13
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 322
2022 Revenue in Millions : 316
Growth (%) : 3
Main Therapeutic Indication : Rare Disease
Currency : USD
2014 Revenue in Millions :
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Rare Disease
Currency : USD
2015 Revenue in Millions : 4
2014 Revenue in Millions : 73
Growth (%) : 1725%
Main Therapeutic Indication : Rare Diseases
Currency : USD
2016 Revenue in Millions : 112
2015 Revenue in Millions : 70
Growth (%) : 61
Main Therapeutic Indication : Rare Diseases
Currency : USD
2017 Revenue in Millions : 156
2016 Revenue in Millions : 131
Growth (%) : 19
Main Therapeutic Indication : Rare Diseases
Currency : USD
2018 Revenue in Millions : 180
2017 Revenue in Millions : 142
Growth (%) : 26%